Belimumab in the treatment of systemic lupus erythematosus with juvenile onset: Results of a single-center retrospective study

The treatment of systemic lupus erythematosus with juvenile onset (jSLE) remains a difficult task, taking into account the more aggressive course of the disease, requiring the appointment of various therapy regimens, including mainly a combination of high doses of glucocorticoids (GC) with immunosuppressive drugs, which on the one hand improves control by the course of the disease, but on the other hand leads to an increase in serious adverse effects from therapy. Modern therapy capabilities have improved significantly with the advent of the belimumab – first and alone registered biologics for children with SLE.

The aim of the study – based on an open single-center retrospective study, to analyze the efficacy and safety of belimumab in children with SLE.

Material and methods. The study included all patients with jSLE who were observed in the pediatric department of V.A. Na sonova Research Institute of Rheumatology and received at least 1 infusion of belimumab. Diagnosis of SLE based on 2012 SLICC (Systemic Lupus Erythematosus International Collaborating Clinics) criteria. The efficacy of therapy was evaluated among patients who received belimumab for 6 months or more, and safety in all who received at least 1 infusion.

Results. The study included 31 patients, 24 girls/7 boys. The median (Me) age at onset of the disease was 12.6 [10.18; 13.5] years, the Me duration of the disease at the time of initiation of belimumab therapy was 2.15 [0.9; 4.4] years. The Me activity on the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) at the time of diagnosis verification was 12 [9; 17.5], at the time of start of belimumab – 8 [6; 12], 35.5% patients had severe activity, 51.6% – moderate, 12.9% – mild activity. The dose of GC per os at start of belimumab was 15 [10; 21.25] mg/day, 32.26% of patients received a high dose of GC, 54.84% – moderate dose, 12.9% – low dose. 9 patients had SDI (Systemic Lupus International Collaborating Clinics Damage Index) ≥1, Me – 1 [1; 2]. After 6 months of therapy, the Me of disease activity according to SLEDAI was 4 [2; 6], the dose of GC per os was reduced to 10 [8.25; 17.5] mg/day. In 15 patients, a decrease in antiDNA was recorded (57.7% of those who initially had elevated values of antiDNA), in 9 the level of complement was normalized (50% of those who initially had hypocomplementemia). After 12 months of therapy, the Me of SLEDAI was 4 [2; 4] (p=0.034), the dose of GC per os was 5 [5; 8.125] mg/day (p=0.012). 5 patients completed therapy within 12 months or more: 1 patient – remission, 4 patients – secondary inefficiency. Belimumab treatment was well tolerated, with the exception of three cases of serious adverse reactions (9.7%): prolonged diarrheal syndrome (after the 1st infusion), Lyell’s syndrome (after the 2nd infusion), infusion reaction (during the 2^nd infusion). During the therapy of belimumab, no new damage were recorded; in 2 patients there was a decrease in the SDI.

Conclusion. Belimumab therapy in patients with jSLE demonstrated high efficacy with a decrease in the activity of the disease according to SLEDAI, normalization of antiDNA and complement, the possibility of a significant reduction the dose of GC, the absence of progression of the SDI with a good safety profile in the vast majority of patients.

1. Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi: 10.1002/art.40697

2. Aseeva EA, Lila AM, Soloviev SK, Nasonov EL, Glukhova SI. Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology. Modern Rheumatology Journal. 2022;16(5):13-21 (In Russ.)] doi: 10.14412/1996-7012-2022-5-13-21

3. Alexander T, Hedrich CM. Systemic lupus erythematosus – Are children miniature adults? Clin Immunol. 2022;234:108907. doi: 10.1016/j.clim.2021.108907

4. Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542-1550. doi: 10.1177/0961203316644333

5. Guzman M, Hui-Yuen JS. Management of pediatric systemic lupus erythematosus: Focus on belimumab. Drug Des Devel Ther. 2020;14:2503-2513. doi: 10.2147/DDDT.S216193

6. Chen YC, Hsu CY, Tsai MC, Fu LS, Huang YC. Remission and long-term remission of pediatric-onset systemic lupus erythematosus. Front Pediatr. 2023;11:1272065. doi: 10.3389/fped.2023.1272065

7. Smith EMD, Tharmaratnam K, Al-Abadi E, Armon K, Bailey K, Brennan M, et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022;61(8):3378-3389. doi: 10.1093/rheumatology/keab915

8. Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi: 10.14412/1995-4484-2019-3-40

9. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.)]. doi: 10.47360/1995-4484-2021-367-383

10. Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10-17. doi: 10.1177/0961203314547793

11. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. Paediatr Drugs. 2021;23(4):331-347. doi: 10.1007/s40272-021-00457-z

12. Kaleda MI, Nikishina IP, Nikolaeva EV, Shapovalenko AN, Fedorov ES, Pachkoria TN. Rituximab for rheumatic diseases in children: Results of a retrospective study of the safety of therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2): 208-214 (In Russ.)]. doi: 10.47360/1995-4484-2021-208-214

13. Chen F, Zheng Y, Chen X, Wen Z, Xu Y, Yang J, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022;13:940416. doi: 10.3389/fimmu.2022.940416

14. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066-1073. doi: 10.1172/JCI38010

15. Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101

16. Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: An acrossstudy comparison. RMD Open. 2021;7(3):e001747. doi: 10.1136/rmdopen-2021-001747

17. Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus. Clin Pharmacol Drug Dev. 2021;10(6):622-633. doi: 10.1002/cpdd.889

18. Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288-2295. doi: 10.3899/jrheum.150470

19. Zeng P, Zeng HS, Tang XM, Zhang QY, Dang XQ. Efficacy and safety analysis of belimumab for 28 weeks in real-world Chinese children with systemic lupus erythematosus: A retrospective multicenter pilot study. Chin J Pract Pediatr. 2021;36:858-368. doi: 10.19538/j.ek2021110612

20. Wang D, Shan C, Liu J, Zhang R, Zhu G, Gao T, et al. Efficacy and safety of belimumab for the treatment of refractory childhoodonset systemic lupus erythematosus: A single-center, real-world, retrospective study. Front Immunol. 2022;13:1067721. doi: 10.3389/fimmu.2022.1067721

21. Wang L, Liang X, Cao Z, Wang D, Luo Y, Feng Y, et al. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: A prospective analysis from a multicentre study. Rheumatology (Oxford). 2024;63(5):1437-1446. doi: 10.1093/rheumatology/kead406

22. Kang M, Zhu J, Xu YJ, Li SN, Lai JM. [Efficacy and safety of belimumab treatment in childhood-onset systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi. 2022;102(48):3881-3885 (In Chinese). doi: 10.3760/cma.j.cn112137-20220302-00438

23. Roberts JE, Burn C, Sadun RE, Smitherman EA, Wenderfer SE, Son MBF. Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study. Lupus. 2023;32(9):1111-1116. doi: 10.1177/09612033231187752

24. Akbar L, Alsagheir R, Al-Mayouf SM. Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus. Eur J Rheumatol. 2020;7(4):184-189. doi: 10.5152/eurjrheum.2020.20087

25. Fontana F, Alfano G, Leonelli M, Cerami C, Ligabue G, Spinella A, et al. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: A case report. BMC Nephrol. 2018;19(1):276. doi: 10.1186/s12882-018-1066-3

26. Hu Y, Yuan J, Wang B, Ma L, Zha Y. Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A case report. Medicine (Baltimore). 2023;102(34):e34800. doi: 10.1097/MD.0000000000034800

27. Zeng HQ, Lu XP, Yan ZB, Ye ZZ. First case presentation of refractory pediatric bullous lupus erythematosus (BSLE) treatment with belimumab. Eur Rev Med Pharmacol Sci. 2022;26(21): 7980-7985. doi: 10.26355/eurrev_202211_30151

28. Lou L, Guo H, Shao M. Systemic lupus erythematosus complicated with Fanconi syndrome: A case report and literature review. Front Pediatr. 2024;11:1230366. doi: 10.3389/fped.2023.1230366

29. Kaleda MI, Nikishina IP, Firsa AV. Belimumab in a patient with systemic lupus erythematosus with juvenile onset and steroid-induced diabetes: Clinical case. Current Pediatrics. 2023;22(6):546-553 (In Russ.)]. doi: 10.15690/vsp.v22i6.2649

30. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473

31. Lattanzi B, Consolaro A, Solari N, Ruperto N, Martini A, Ravelli A. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S112-S117. doi: 10.1002/acr.20623

32. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762

33. Smith EMD, Aggarwal A, Ainsworth J, Al-Abadi E, Avcin T, Bortey L, et al.; cSLE T2T International Task Force. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force. Ann Rheum Dis. 2023;82(6):788-798. doi: 10.1136/ard-2022-223328

34. Williams CEC, Lamond M, Marro J, Chetwynd AJ, Oni L. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). Clin Rheumatol. 2023;42(12):3189-3200. doi: 10.1007/s10067-023-06781-8

35. Vivarelli M, Colucci M, Gargiulo A, Bettini C, Lo Russo A, Emma F. Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: The BELNEPH study. Pediatr Nephrol. 2022;37(2):377-383. doi: 10.1007/s00467-021-05175-9

36. Van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: A phase III study extension. Rheumatology (Oxford). 2020;59(2):281-291. doi: 10.1093/rheumatology/kez279